Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Hepatology. 2018 Jul 16;68(4):1347–1360. doi: 10.1002/hep.29914

Figure 5. NET inhibition reduces progression of NASH to HCC.

Figure 5

(A) NET inhibition for 20 weeks with daily DNase treatment, or by gene knockout for peptidylarginine deaminase (PAD4KO) significant reduces tumor formation at 20 weeks. (B) Tumor size analysis of the largest 3 tumors found at a random section through the liver revealed significantly reduced tumor sizes in DNase-treated mice and PAD4−/− mice, compared to untreated wild type STAM mice. (C) Serum IL-6 levels remain decreased, suggesting that NET inhibition persistently alters the inflammatory environment in which HCC arises.